Key facts
- This page summarizes James Sapirstein's Form 4 filing for Entero Therapeutics, Inc. (ENTO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jul 2024, 14:33.
James Sapirstein - 02 Jul 2024 Form 4 Insider Report for Entero Therapeutics, Inc. (ENTO)
- Reporting relationship
- Chairman and CEO, Director
- Issuer ticker
- ENTO
- Reported as of
- 02 Jul 2024
- Net transaction value
- -$1,379
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2024, 14:33:15 UTC
- Prior SEC filing
- 27 Jun 2024
- Next SEC filing
- 30 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Sapirstein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Sapirstein filed Form 4 for Entero Therapeutics, Inc. (ENTO) on 03 Jul 2024.
Change
- Previous filing in this sequence was filed on 27 Jun 2024.
- Current net transaction value: -$1,379.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENTO
transaction
Common Stock
Sale
- Transaction value
- $1,379
- Shares
- -1,289
- Change %
- -3.5%
- Price
- $1.07
- Shares after
- 35,816
- Date
- 02 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Footnote F2
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.05 - $1.16, inclusive. The Reporting Person undertakes to provide Entero Therapeutics, Inc. ("Entero"), any security holder of Entero, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Footnote F3
Includes unvested RSUs.